AI Summary & Key Takeaways
AI InsightIn group 1, BCVA decreased from the logarithm of the minimum angle resolution (log MAR) of 0.59 ± 0.39 to 0.70 ± 0.41 log MAR in the fi nal examination (p = 0.016), CMT initial 355.562 ± 95.54 μm decreased from to 296,76 ± 105,03 μm at the last examination (p
📌 3 Key Takeaways
Abstract
Purpose: To compare visual and anatomical results of anti- vascular endothelial growth factor (VEGF) combined with photodynamic therapy (PDT) versus only performing anti- VEGF therapy in eyes with polypoidal choroidal vasculopathy (PCV). Materials and Methods: Retrospective review of 60 PCV patients who underwent anti- VEGF combined with PDT (Group 1) or solely performing anti- VEGF therapy (Group 2) were enrolled. The best corrected visual acuity (BCVA), central macular thickness (CMT), presence of subretinal fl uid (SF) were compared among the groups during the follow-up periods at baseline, 1st month, 3rd month, 6th month, 9th month, 12th month,18th month, 24th month and fi nal visit, respectively. Results: The mean age of the patients was 71.96 ± 8.50 years (range, 52-88 years), and the mean follow-up period was 53.83 ± 14.86 (range, 20-85 months). The mean number of injections was observed as 10.56 ± 1.88 (range, 7 -15) in the fi rst group and 11.83 ± 2.61 (range, 7 - 17) in the second group, respectively (p = 0.039). In group 1, BCVA decreased from the logarithm of the minimum angle resolution (log MAR) of 0.59 ± 0.39 to 0.70 ± 0.41 log MAR in the fi nal examination (p = 0.016), CMT initial 355.562 ± 95.54 μm decreased from to 296,76 ± 105,03 μm at the last examination (p